Literature DB >> 11163751

Synthesis and in vitro evaluation of 123I-labelled human recombinant annexin V.

C Lahorte1, G Slegers, J Philippé, C Van de Wiele, R A Dierckx.   

Abstract

Annexin V was radiolabelled with iodine-123 in order to develop a SPECT-ligand for imaging atherosclerosis and apoptosis. Iodination by means of electrophylic substitution resulted in radiochemical yields up to 70% and specific activities of 7.4-92.5 MBq/microg protein. Binding experiments with blood platelets indicated that 123I-labelled annexin V remained its biological activity.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11163751     DOI： 10.1016/s1389-0344(00)00062-9

Source DB:  PubMed          Journal:  Biomol Eng        ISSN： 1389-0344


  4 in total

Review 1.  Apoptosis-detecting radioligands: current state of the art and future perspectives.

Authors:  Christophe M M Lahorte; Jean-Luc Vanderheyden; Neil Steinmetz; Christophe Van de Wiele; Rudi A Dierckx; Guido Slegers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-12       Impact factor: 9.236

2.  Detection of apoptotic cell death in the thymus of dexamethasone treated rats using [123I]annexin V and in situ oligonucleotide ligation.

Authors:  Katerina Zavitsanou; Vu Nguyen; Ivan Greguric; Janette Chapman; Patrice Ballantyne; Andrew Katsifis
Journal:  J Mol Histol       Date:  2007-06-29       Impact factor: 2.611

3.  Investigation of a potential scintigraphic tracer for imaging apoptosis: radioiodinated annexin V-Kunitz protease inhibitor fusion protein.

Authors:  Mei-Hsiu Liao; Tong-Rong Jan; Chao-Chih Chiang; Kuo-Chen Yen; Tse-Zung Liao; Ming-Wei Chen; Chin-Wen Chi; Tze-Chein Wun; Tzu-Chen Yen; Shiaw-Pyng Wey
Journal:  J Biomed Biotechnol       Date:  2011-04-27

Review 4.  Avenues to molecular imaging of dying cells: Focus on cancer.

Authors:  Anna A Rybczynska; Hendrikus H Boersma; Steven de Jong; Jourik A Gietema; Walter Noordzij; Rudi A J O Dierckx; Philip H Elsinga; Aren van Waarde
Journal:  Med Res Rev       Date:  2018-03-12       Impact factor: 12.944
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.